Cemiplimab R&D and manufacturer

Cemiplimab (Cemiplimab) is jointly developed by the American pharmaceutical company Regeneron Pharmaceuticals and the French pharmaceutical company Sanofi. The two companies have collaborated on the research, development, manufacturing and commercialization of cimepilimab, a collaboration designed to drive innovation in the field of immunotherapy.

Cimeplimab is not currently available in China, so patients cannot purchase it domestically and need to purchase cimeplimab through overseas channels. There are only cimepri monoclonal original drugs abroad, mainly European and American versions. The European version is about 40,000, and the American version is about 100,000. Both are original drugs, and their drug ingredients and efficacy are the same.

Regeneron Pharmaceuticals was founded in 1988 and is headquartered in Tarrytown, New York, USA. The company focuses on biotechnology research and drug development to improve patients' quality of life, particularly in the areas of cancer, eye disease, cardiovascular disease and immunological diseases. Regeneronhas extensive research experience in innovative antibody drugs, including cimepilimab.

Sanofiis a global pharmaceutical company headquartered in France, founded1973. It is an integrated pharmaceutical company with a broad pharmaceutical product portfolio including biologics, drugs, vaccines and consumer healthcare products. Sanofi is actively engaged in drug research and innovation on a global scale, aiming to meet the different medical needs of patients around the world. Through its partnership with Regeneron, Sanofi strengthens its presence in the immunotherapy space to provide new cancer treatment options.

Cimepilimab is the product of a collaboration between the two pharmaceutical companies and is an important innovation in the field of immunotherapy. It has been approved to treat patients with advanced squamous cell non-small cell lung cancer (SCC) and certain cutaneous squamous cell carcinomas (SCC), providing new hope for patients for whom traditional treatments are ineffective or inappropriate. This successful collaboration demonstrates how collaboration between multinational pharmaceutical companies can accelerate the development of innovative medicines and bring innovation to patients around the world.